top of page

The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease

  • blonca9
  • Apr 10, 2024
  • 1 min read

Bill Sibold describes how Madrigal has prepared for the launch, visually illustrates how the medicine is meant to impact disease progression, and shares his opinion on whether GLPs could potentially compete in this indication one day in the future.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page